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We report microbiologic analysis of 786 lymph node
biopsy specimens from patients with suspected cat-scratch
disease (CSD). The specimens were examined by stan-
dard, cell culture, and molecular methods. Infectious
agents were found in samples from 391 (49.7%) of 786
patients. The most commonly identified infectious agent
was Bartonella henselae (245 patients, 31.2%), the agent
of CSD. Mycobacteriosis was diagnosed in 54 patients
(6.9%) by culture and retrospectively confirmed by using a
specific real-time PCR assay. Neoplasm was diagnosed in
181 specimens suitable for histologic analysis (26.0%) from
47 patients. Moreover, 13 patients with confirmed
Bartonella infections had concurrent mycobacteriosis (10
cases) or neoplasm (3 cases). Adiagnosis of CSD does not
eliminate a diagnosis of mycobacteriosis or neoplasm.
Histologic analysis of lymph node biopsy specimens should
be routinely performed because some patients might have
a concurrent malignant disease or mycobacteriosis.
L
ymph node enlargement is a common medical prob-
lem. Infections caused by bacterial, viral, and proto-
zoal agents are the most typical cause of localized
lymphadenopathy, but malignancies or lymphoprolifera-
tive diseases are also often found (1). Physicians must dif-
ferentiate malignant lymphadenopathies or infectious
diseases that require special care from benign reactive
lymphadenopathy or self-limiting adenitis. 
In a large number of patients, the causes of lym-
phadenopathy remain undiagnosed. Causes of lym-
phadenopathy other than neoplasm that require urgent
medical attention include tuberculosis and HIV infection.
During the past 15 years, Bartonella henselae, the
causative agent of cat-scratch disease (CSD), has been
reported as a common cause of localized lymphadenopa-
thy (1–3). Diagnostic techniques for Bartonella-related
infections include culture of the pathogen (4,5), detection
of organisms in lymph nodes by immunofluorescence (6),
molecular techniques including PCR amplification of
Bartonella spp. genes (7,8), and serologic analysis (9,10).
B. henselae is not commonly isolated from CSD patients
(4,11), and PCR-based detection of various target genes of
Bartonella species in tissue specimens has become the
most widely accepted way of diagnosing CSD (7,8). 
Serologic analysis is a minimally invasive diagnostic
technique that has been extensively evaluated for the diag-
nosis of CSD (9,10,12). The sensitivity of serologic tests
varies from 1 laboratory to another, ranging from nearly
100% to <30% (9). Specificity may also vary, and a speci-
ficity >95% may be achieved by using commercial tests
with immunoglobulin G cutoff titers >128 (10).
As a national reference center for rickettsioses and bar-
tonelloses, we routinely receive lymph node biopsy speci-
mens from patients with suspected CSD. In this study, we
analyzed a large collection of lymph node biopsy samples
obtained from January 2001 through August 2005 using
microbial cultures (blood agar culture and cell culture) and
16S rDNA- and Bartonella-specific PCR. Our objective
was to define the frequency of B. henselae and other bac-
terial infections in patients with suspected CSD in France.
Methods
Patients
We studied lymph node biopsy specimens from patients
with suspected CSD that were collected from January 2001
through August 2005. Tissues specimens sent to our
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patients and outpatients throughout France. We receive
either the entire lymph node or a fragment of it; the speci-
mens were sent either frozen or in transport media. This
factor is crucial because most of the specimens received
were not in suitable condition for histologic analysis. A
definitive diagnosis of CSD was defined as a biopsy sam-
ple that was positive by PCR for 2 different target genes of
Bartonella spp. (6). If a specimen had been previously ana-
lyzed and B. henselae was reported (7), the specimen was
excluded from the present study.
Detection of Bartonella DNA in Tissue Specimens
Total genomic DNAwas extracted from samples with a
QIAamp tissue kit (Qiagen, Hilden, Germany) as previ-
ously described (7). Samples were handled under sterile
conditions to avoid cross-contamination. Genomic DNA
was stored at 4°C until used as template in PCR assays.
The primers used for B.  henselae amplification and
sequencing (internal transcribed spacer [ITS] region and
pap31 gene) have been previously evaluated (6,7). Up to
10 samples were tested, along with negative controls
(DNA from noninfected lymph nodes and sterile water)
and a positive control (DNA from B. elizabethae for the
ITS region, GenBank accession no. L35103, and DNA
from B. henselae Houston-I for the pap31 gene, GenBank
accession no. AF001274).
Detection of Bacteria in Tissue Specimens
Nucleic acids were extracted with a QIAamp tissue kit
(Qiagen) and PCR performed with universal 16S rDNA
primers fD1 and rp2 (Eurogentec, Seraing, Belgium) (13)
and Taq DNA polymerase (GIBCO-BRL Life
Technologies, Gaithersburg, MD, USA). Amplification
and sequencing of products were conducted as previously
described (14). Up to 10 samples were tested, along with
negative controls (noninfected lymph node and sterile
water) and positive controls (B. henselae Houston-I and
Staphylococcus aureus (ATCC 29213). The 16S rDNA
sequences obtained were compared with all bacterial 16S
rRNA sequences available in the GenBank database by
using the Blastn version 2.2.2 program (National Center
for Biotechnology Information, Bethesda, MD, USA). The
efficiency of DNA extraction and presence of inhibitors in
samples that were negative by PCR were tested by using
primers that targeted a fragment of the human β-globin
gene as previously described (15).
Detection of B. henselae in Lymph Nodes
We confirmed B. henselae in lymph nodes of patients
with CSD by using a specific monoclonal antibody for B.
henselae as previously described (6). The slides were air-
dried and fixed with methanol for 10 minutes at room tem-
perature before testing with an immunofluorescence assay
(6). The sensitivity and specificity of this assay and anti-
body were previously reported to be 79.6% and 92.5%,
respectively (6).
Culture Methods
Lymph node biopsy specimens were placed on blood
agar plates, incubated at 37°C in an atmosphere of 5%
CO2, and examined weekly for growth during a 2-month
period. This process resulted in isolation of either
Bartonella or mycobacteria (16). Specimens were also
placed on human embryonic lung cells in shell vials and
incubated at 37°C in an atmosphere of 5% CO2 as previ-
ously described (4,17). From January 2002 to August
2005, specimens were also incubated onto horse blood
agar supplemented with hemin (100 mg/L). This procedure
has been reported to improve the isolation rate of B. hense-
lae and can also support growth of rapidly growing
mycobacteria (11,16). Specimens were also cultured under
anaerobic conditions. Bartonella isolates were identified
by PCR and sequencing as described above; other bacteri-
al isolates were identified by using standard bacteriologic
methods. Samples from which mycobacteria were isolated
were reanalyzed retrospectively by real-time PCR with
modified primers and probes targeting the ITS region as
previously described (18).
Histologic Analysis
Samples that had not been frozen (181 specimens) were
fixed in formalin and processed for histologic analysis.
Stains used included Gram, hematoxylin and eosin, period-
ic acid–Schiff, Ziehl-Neelsen, and Warthin-Starry.
Statistical Analysis
Two groups of patients were defined for demographic
data comparisons: CSD patients (detection of Bartonella
DNA) and non-CSD patients (no detection of Bartonella
DNA). For data comparison, the Student t test or χ2 test was
performed by using EpiInfo version 6.0 software (Centers
for Disease Control and Prevention, Atlanta, GA, USA).
Results
Diagnoses in Patients with Lymphadenopathy
We tested 786 lymph node biopsy specimens from
patients with suspected CSD. Only 181 specimens were
suitable for histologic analysis. Neoplasm was diagnosed
by histologic analysis in 47 (26.0%) of 181 patients (6 with
skin carcinomas, 1 with acute leukemia, 24 with lym-
phomas, 12 with Hodgkin disease, and 4 with Kaposi sar-
coma). Bacteria were cultured from 143 specimens
(18.2%), and mycobacteria were the most frequently
recovered organisms (54 [6.9%] of 786) on blood agar or
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mycobacteria were retrospectively confirmed by using
real-time PCR targeting the ITS region. Other common
bacteria recovered either by culture or PCR were staphylo-
cocci (26 cases) and Propionibacterium acnes (15 cases).
B. henselae was cultured and successfully passaged from 1
lymph node, and B. quintana was cultured and amplified
from 1 lymph node. Fastidious bacteria were cultured from
lymph nodes by the shell vial cell culture: 2 isolates of
Coxiella burnetii and 1 isolate of Francisella tularensis,
which has been previously reported (19) (Table 1).
Anaerobic bacteria cultured from lymph nodes included
Fusobacterium spp. (4 specimens), Prevotella sp. (1 spec-
imen), and Clostridium perfringens (1 specimen).
Amplification of the 16S rDNA gene for common bac-
teria was performed on all specimens. Positive results were
obtained for 236 patients (30.0%), and B. henselae was the
most frequently amplified bacterium (122 cases, 51.7%).
Other bacteria commonly detected included mycobacteria,
staphylococci, streptococci, and P.  acnes (Table 1).
Fastidious bacteria were isolated from 5 lymph nodes: C.
burnetii (3 cases), F. tularensis (1 case), and Tropheryma
whipplei (1 case). These 5 diagnoses were confirmed by a
second specific PCR with primers and probes routinely
used in our laboratory. Using specific primers for the ITS
region and pap31 gene of Bartonella spp., we identified
Bartonella spp. in 245 patients (31.2%), including 122
patients identified by PCR with primers for the 16S rDNA
gene. No discordance was observed between the ITS
region and the pap31 gene. 
When compared with specific detection of Bartonella
DNA, specificity of the 16S rDNA PCR was 100% but
sensitivity was low (49.8%, 122 of 245 lymph nodes were
positive). Positive and negative controls showed expected
results in all tests. All but 1 of the sequences of the ITS
region and pap31 genes we obtained were identical to
those of B. henselae reported in GenBank. In 1 patient, the
sequences obtained were identical to those of B. quintana.
Among these 245 samples positive for Bartonella, 216
were also tested by direct immunofluorescence assay with
monoclonal antibodies to B.  henselae, of which 166
(76.9%) were positive.
Atotal of 391 (49.7%) of 786 patients had an infectious
disease (including the 10 patients whose specimens were
B. henselae–positive by PCR and showed mycobacterial
infection), 47 had neoplasm (including 3 specimens with
B. henselae–positive PCR result), and 351 (44.6%) had no
identified cause for their lymphadenopathy (Table 1). On
the basis of these results, we divided the patients into 2
groups: patients with a positive PCR result for Bartonella
(n = 245) (CSD group) and the remaining patients (n =
541) (non-CSD group).
Comparison of Demographic Data 
between Patient Groups
The mean ± standard deviation (SD) age was 30.2 ±
20.4 years (range 1–94 years) in 245 patients with proven
B. henselae or B. quintana lymphadenopathy (CSD group)
versus 31.6 ± 20.7 years (range 4 months to 86 years) in
the non-CSD group. Most patients with B. henselae CSD
were <25 years of age (p = 0.032) (Figure 1). The mean ±
SD ages of patients with neoplasm (46.2 ± 22.6 years,
range 7–86 years) and mycobacterioses (39.5 ± 22.2 years,
range 1–84 years) were greater than the mean ± SD age of
patients with CSD (p<0.05 by Student t test) (Table 2). The
sex ratio (male:female) was 1.28 in the CSD group and
1.50 in the non-CSD group, but this difference was not sig-
nificant (p>0.05) (Table 2). In the CSD group, 89 of the
lymph node biopsy specimens were from axillary nodes
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were from cervical nodes (33.1%).
We found that 13 of 245 patients with CSD had concur-
rent lymph node disease (Table 2). Ten had mycobacterio-
sis proven by culture (5 with M. tuberculosis, 3 with M.
avium, 1 with M. fuerthenensis, and 1 with M. gordonae),
and 3 had neoplasm (2 with lymphoma and 1 with
Hodgkin disease). The mean ± SD age of these 13 patients
(49.7 ± 16.0 years, range 27–72 years) was higher than the
mean ± SD age of the remaining 232 patients with only
CSD (p<0.05 by Student t test). Only 4 lymph node biop-
sy specimens from the 10 patients with concurrent
mycobacteriosis were positive by Ziehl-Neelsen staining.
Six of 10 lymph node biopsy specimens were positive in a
direct immunofluorescence assay with monoclonal anti-
bodies for B. henselae (Figure 2) as previously described
(6).
Of the 3 patients with CSD and concurrent neoplasm, a
positive PCR result for the 16S rDNA gene was obtained
with DNA from 1 lymph node (B. henselae). Two of 3
lymph nodes were positive in a direct immunofluorescence
assay with monoclonal antibodies to B. henselae as
described previously (6). As expected, the number of
patients with either mycobacteriosis or neoplasm in the
non-CSD group was higher than in the CSD group (p =
0.014; n = 181 patients).
Discussion
Culture and PCR were used to examine lymph node
biopsy specimens from patients with suspected CSD.
These methods, i.e., blood agar and cell culture (20),
molecular biology with PCR for the 16S rDNA gene (14),
PCR with 2 specific genes from Bartonella (6,7), and his-
tologic analysis (20), have been previously validated and
are routinely used for examination of lymph node samples.
Our report describes an extensive study on lymph nodes
using culture, 16S rDNA PCR amplification, and amplifi-
cation of target genes of Bartonella spp. 
Our objective was to define all bacterial causes of lym-
phadenopathies for samples initially sent to our center for
detection of CSD. In the patients we studied, 50% had
infectious diseases, and the most common causative agent
was B. henselae; ≈30% of suspected patients were PCR
positive (CSD group). Sensitivity of PCR with the 16S
RNA gene to diagnose CSD was lower than was
Bartonella-specific PCRs. The sensitivity of PCR assays
with the 16S rRNAgene for the diagnosis of CSD has been
reported to vary from 43% to 100%, depending on the
primers used and the definition of a positive case (21,22).
In our laboratory, PCR with specific primers against
Bartonella genes is more sensitive and specific in the diag-
nosis of CSD.
In a recent study in Germany, B. henselae was the
causative agent of head and neck lymphadenopathy in 61
(13.4%) of 454 patients (1). As in our study, B. henselae
was the most common organism responsible for lym-
phadenopathy in adults and children (1). However, our
higher percentage of positive PCR results was because
specimens sent to our reference laboratory were from
patients with suspected CSD. Many cases of CSD remain
unrecognized because serologic or molecular analyses are
not routinely used. We observed a low isolation rate for B.
henselae on axenic media or in cell culture, only 1 suc-
cessfully passaged isolate among the 245 PCR-positive
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Figure 1. Distribution of patients by age and group. Cat-scratch
disease (CSD) group, patients with Bartonella-positive PCR
results in lymph node samples; Non-CSD group, patients with
Bartonella-negative PCR results. For patients <25 years of age,
p = 0.032 for CSD group versus non-CSD group.samples, which is consistent with previous findings (4,8).
This rate did not improve when we used an enriched medi-
um designed to improve isolation of B. henselae (11). A
recently developed enriched liquid medium for growth of
Bartonella strains (23) may be useful in obtaining more
isolates of B. henselae from patients with CSD. However,
in many lymph nodes negative by culture, we observed
bacteria by direct immunofluorescence, which suggests
that bacteria in lymph nodes are not viable (6). Consistent
with this finding was that most nodes were necrotic at
histopathologic examination (data not shown). One lymph
node was positive for B. quintana by culture and PCR as
previously reported (24).
The long incubation time needed for isolation of
Bartonella allows us to isolate mycobacterial strains by
using blood agar culture (16). We found mycobacteria inci-
dentally and not because of a specific search. Moreover,
even if mycobacteria grew well in blood agar plates (16),
sensitivity of culture from lymph nodes is not 100%. This
fact means that the percentage of mycobacterial infections
in our study was probably underestimated because specif-
ic PCR for mycobacteria was only performed retrospec-
tively in culture-positive specimens. On the basis of these
results, we now routinely perform Ziehl-Neelsen staining
and PCR to detect mycobacteria in all specimens. 
Before the discovery of B. henselae and the use of PCR
for its diagnosis, mycobacteria were the most frequent
infectious agents causing lymphadenopathy (25), and
staphylococci and group A streptococci were the main
causes of acute adenitis. In our study, mycobacteria were
the second most common infectious cause of lymph node
enlargement; >6.9% of patients were infected. The 16S
rRNA PCR in our study had a lower sensitivity than cul-
ture in the diagnosis of mycobacterial infection. This find-
ing may have resulted from sample pretreatment to
adequately purify DNA (26). Freidig et al. found that 24
(5.7%) of 419 lymph nodes were enlarged because of
mycobacterial infection (Table 3) (27). Similar incidences
have been reported by Doberneck (28) and Anthony and
Knowles (29) (Table 3). Higher incidences of mycobacte-
rial infections (27 [16.6%] of 163 lymph node biopsy spec-
imens) were reported by Roberts and Linsey (25). In our
study, 76% of mycobacterial infections were M. tuberculo-
sis; 54% were M. tuberculosis in the study by Freidig et al.
(27). This finding is consistent with the fact that the inci-
dence of typical and atypical mycobacterial adenitis is age
dependent; typical adenitis is more common in adults, and
atypical adenitis is more common in children (30).
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Figure 2. Detection of Bartonella henselae in the lymph node of a
patient with cat-scratch disease and tuberculosis by direct immuno-
fluorescent assay with a monoclonal antibody (magnification ×400).Other agents found in our study were staphylococci and
miscellaneous aerobic and anaerobic bacteria. Isolates of
coagulase-negative staphylococci or P. acnes may be con-
sidered contaminants, but the remaining organisms are
pathogens and should be considered causative agents of
lymph node enlargement (31). We found that rare or fastid-
ious organisms may be the cause of infectious adenitis.
Such situations have been previously reported, especially
infections with Nocardia spp. (32), C. burnetii (33), F.
tularensis (34), or T. whipplei (35). Only because we used
cell cultures in shell vials were we able to culture C. bur-
netii and F. tularensis in our study. Similarly, additional
cases with these fastidious organisms, as well as 1 case of
infection with T. whipplei, were diagnosed because of sys-
tematic use of broad-range PCR on lymph nodes.
The cause of 351 cases of lymphadenopathy in this
study could not be determined. Several reasons and limita-
tions may explain this result. First, histologic data were
obtained for only 23% of the lymph node specimens
because most were sent to our center frozen or were too
small. In 181 specimens, neoplasms may represent >25%
of cases of suspected CSD. Thus, a similar proportion of
neoplasms may be present in the remaining 605 speci-
mens. For practical purposes, neoplasm can only be diag-
nosed by histopathologic analysis. Thus, lymph node
excision is crucial in the diagnosis of malignant processes.
Another limitation of our study was that we did not test for
fungi or viruses that may also represent causes of lym-
phadenopathies. Mycobacterial infections in our study
were diagnosed by culture and confirmed retrospectively
by using a real-time quantitative PCR. We believe that the
systematic use of real-time PCR for detection of mycobac-
teria will likely increase the percentage of such infections
as causes of lymphadenopathies.
Previous studies reported that the percentage of undiag-
nosed cases varied from 17.2% to 39.7% (Table 3), and
malignant processes were more common than infectious
diseases. In more recent studies, percentages of lymph
node specimens with malignant processes were lower
(11.5%–17.3%), and infectious diseases were more com-
mon (17.7%–48.6%) (1,8,36) (Table 3).
We have showed that neoplasm could be clinically mis-
diagnosed as CSD. This finding was probably underesti-
mated because we had previously analyzed lymph nodes
only by culture and detection of fastidious organisms.
Moreover, only fresh samples can be used in histologic
analysis. Our results reemphasize that CSD may be misdi-
agnosed as neoplasm, and we believe that lymph node
excision and histologic analysis are critical for accurate
diagnosis.
We found that 13 Bartonella-positive patients (4.2%)
had concurrent disease; 10 had mycobacteriosis (Figure 2),
and 3 had neoplasm. These patients were older than those
with CSD alone. However, neoplasm and mycobacterial
infection was less common in patients with CSD than in
those without CSD (p = 0.014, n = 181 patients). In the
only report of coincidental CSD and neoplasm, Ridder et
al. found 2 patients with squamous cell carcinoma and 2
patients with malignant B-cell lymphoma on the basis of
high antibody titers to B. henselae (1). A high prevalence
of B. henselae–specific antibodies in HIV-positive patients
with generalized lymphadenopathy and patients with non-
Hodgkin lymphoma has also been reported (37).
Explanations for such associations are unknown, and the
frequency of asymptomatic patients with CSD is not
known. One may speculate that Bartonella infections pro-
duce more symptoms in patients with HIV infections,
mycobacterial infections, or neoplasm or cause chronic
infection in such cases.
In conclusion, lymph node excision and testing by his-
tologic analysis are critical in detecting malignant process-
es and mycobacterial infections, even in patients found to
have CSD by PCR. A diagnosis of CSD does not preclude
other concurrent diseases, and their presence should rou-
tinely be tested by histologic analysis. In addition to test-
ing pus samples or serologic analysis, biopsy specimens
should be examined by a histologist, as recently proposed
for patients with lymphadenopathy (8,38,39). Our study
also demonstrates the advantage of specific target gene
amplification compared with 16S rDNA gene amplifica-
tion. Moreover, physicians should be aware that CSD can
occur concurrently with neoplasm and mycobacteriosis,
especially in adults >49 years of age.
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